Axovant to Present at 8th Annual SVB Leerink Global Healthcare Conference
February 19, 2019 07:00 ET
|
Axovant Sciences Ltd.
NEW YORK and BASEL, Switzerland, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that Pavan Cheruvu,...
Axovant Announces Formation of Arvelle Therapeutics and Strategic Transition of Legacy Small Molecule Team Into Newly Formed Company
February 14, 2019 07:00 ET
|
Axovant Sciences Ltd.
Transition of small molecule expertise to Arvelle completes transformation of Axovant into a company focused exclusively on gene therapiesAxovant will receive a preferred equity stake in Arvelle,...
Axovant Announces Third Fiscal Quarter 2018 Financial Results and Corporate Updates
February 07, 2019 16:15 ET
|
Axovant Sciences Ltd.
Expanded pipeline with two investigational gene therapy programs licensed from the University of Massachusetts Medical School for the treatment of GM1 gangliosidosis, Tay-Sachs and Sandhoff diseases ...
Axovant Announces Presentation at J.P. Morgan Healthcare Conference and Anticipated 2019 Clinical Development Milestones
January 03, 2019 07:00 ET
|
Axovant Sciences Ltd.
Axovant’s CEO, Pavan Cheruvu, M.D., will be presenting at the J.P. Morgan Healthcare Conference at 8:00 a.m. PST on Thursday, January 10th, 2019Initial clinical data expected in first half of 2019...
Axovant Sciences Announces Pricing of $30 Million Public Offering of Common Shares
December 14, 2018 09:00 ET
|
Axovant Sciences Ltd.
BASEL, Switzerland, Dec. 14, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (Nasdaq: AXON) ("Axovant") today announced the pricing of its underwritten public offering of 30,000,000 of its common shares...
Axovant Sciences Announces Public Offering of Common Shares
December 13, 2018 16:56 ET
|
Axovant Sciences Ltd.
BASEL, Switzerland, Dec. 13, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (Nasdaq: AXON) ("Axovant") today announced that it has commenced an underwritten public offering of its common shares. All of...
Axovant Licenses Investigational Gene Therapies for GM1 Gangliosidosis, Tay-Sachs and Sandhoff Diseases from University of Massachusetts Medical School
December 13, 2018 16:01 ET
|
Axovant Sciences Ltd.
Two novel programs for fatal pediatric diseases deepen Axovant’s neurological gene therapy pipelineAXO-AAV-GM1 expected to enter the clinic in first half 2019, with initial data expected in second...
Axovant Reports Results of Exploratory Phase 2 Clinical Study of Nelotanserin in Lewy Body Dementia Patients Experiencing REM Sleep Behavior Disorder
December 10, 2018 07:00 ET
|
Axovant Sciences Ltd.
Primary efficacy endpoint assessed by sleep laboratory video assessment was not metAxovant is discontinuing clinical development of nelotanserin BASEL, Switzerland, Dec. 10, 2018 (GLOBE NEWSWIRE)...
Axovant Announces Feedback From FDA Meeting Regarding AXO-Lenti-PD for Parkinson’s Disease and Progress in Ongoing SUNRISE-PD Phase 2 Clinical Trial
December 06, 2018 07:00 ET
|
Axovant Sciences Ltd.
Meeting with FDA confirmed that studies previously conducted using first generation ProSavin® may be considered part of a single development program with AXO-Lenti-PDConfirmed with FDA that the...
Axovant Strengthens Team with Additional Expertise to Support Gene Therapy Pipeline
November 26, 2018 08:00 ET
|
Axovant Sciences Ltd.
Greg MacMichael, Ph.D., formerly global head of cell and gene therapy technical development and manufacturing at Novartis, joins Axovant as SVP of technical operationsParag Meswani, Pharm.D., formerly...